Discover Thomson Reuters
By
1 Min Read
July 12 (Reuters) – VIFOR PHARMA AG:
* ANNOUNCES THREE OUTCOMES TRIALS IN HEART FAILURE AND IRON DEFICIENCY
* FURTHER ANALYSIS OF EXISTING DATA SUGGESTS FERINJECT MAY HAVE A POSITIVE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH SYSTOLIC HEART FAILURE Source text – bit.ly/2uc8T0i Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

source